Background: Nestin, a member of the intermediate filament protein family,
INTRODUCTION
Nestin, a member of the class VI intermediate filament protein family, is expressed in normal cells of different tissues and organs. [3] Nestin expression was first reported in progenitor cells of central and peripheral nervous systems. [4] Its expression has since been reported in skeletal and cardiac muscle progenitors, developing tooth buds, testis and hair follicle sheath progenitor cells of the skin, a distribution that suggests that nestin is a www.impactjournals.com/oncotarget potential indicator of proliferative and multipotency status in several types of progenitor cells. [5, [6] [7] [8] [9] [10] [11] Recent reports have indicated that nestin might be linked to malignant characteristics, suggesting that abundant nestin expression correlates with greater malignancy and poorer prognosis in different cancers. Moreover, several studies have also reported that nestin is a marker of cancer stem cells in different malignancies, including brain tumors, uterine cancer, cervical cancer, prostate cancer, bladder cancer, head and neck cancer, ovarian cancer, testicular cancer, pancreatic cancer, and malignant rhabdoid tumors. [12] [13] [14] [15] [16] [17] [18] [19] The TNM (primary Tumor, lymph Nodes, and distant Metastasis) classification system, published by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) for Malignant Tumors, has been used worldwide and across all medical specialties as a cancer-staging technique. [1] The TNM system is based on the anatomic extent of the tumor, as determined clinically and, in most instances, histopathologically, and can facilitate diagnosis, prognosis, treatment and other clinical decisions. [1, 2] Although several articles on the relationship between nestin and cancer stage have been reported, including Masao et al., [20] Shinichiro et al., [21] Chen et al. [22] [23] and Karsten et al. [24] , only that of Karsten et al. reported that high nestin was strongly, and significantly, associated with cancer stage. Because of the relatively small sample sizes and limited statistical power of these individual, inconclusive studies, it is important to summarize the results from different studies to more accurately assess the association of positive/high nestin with cancer stage. To this end, we carried out a meta-analysis of all eligible studies, combining results to produce a single estimate of the major effect with enhanced precision. [25] We further performed a subgroup analysis stratified according to lymph node involvement and cancer category.
RESULTS

Study characteristics
Our search strategy identified 150 potentially relevant studies. After checking the title and abstract, a total of 30 articles consistent with our search criteria were preliminarily chosen for further detailed evaluation. After careful screening, we excluded 16 studies because data were insufficient for analysis. Of the remaining 14 studies, seven did not focus on nestin and cancer staging. Ultimately, seven studies on nestin and cancer staging that included a total of 223 positive/high nestin cases and 460 negative/low case-free controls were deemed eligible for the final analysis. The characteristics of the included studies are listed in Table 1 . All studies were related to clinical research, including three lung cancer studies, one pancreatic cancer study, one prostate cancer study, one gastric adenocarcinoma study, and one oral cancer study. All cancers were confirmed pathologically. The study selection process is shown schematically in Figure 1 .
Meta-analysis results
The frequency of tumors, lymph node involvement, and cancer stage in positive/high and negative/low nestin patients are shown in detail in Table 2 . All TNM staging data were collected, and a subset of lymph node data was extracted.
Seven articles that included a total of 223 cases and 460 controls were used to evaluate the relationship between nestin with cancer stage. The main results of this meta-analysis are indicated in Figure 2 . Overall, there was evidence for an association between positive/high nestin and median/advanced cancer stage in different cancers when all eligible studies were pooled into the metaanalysis. As show in Figure 2 , the significant main effect observed was for nestin and median/advanced cancer stage (positive/high nestin vs. negative/low nestin: OR = 1.90, 95% CI = 1.30-2.78, P = 0.0009).
Four articles that included 110 cases and 277 controls were used to evaluate the relationship between nestin and lymph node involvement. In the analysis stratified by lymph node involvement (N 1-2 vs. N 0 ), as shown in Figure 4 , the main effect remained (positive/ high nestin vs. negative/low nestin: OR = 2.17, 95% CI = 1.26-3.72, P = 0.005). For the analysis stratified by cancer category, three articles that included 87 cases and 207 controls were used to evaluate the relationship between nestin and lung cancer (median or advanced stage vs. early stage). As show in Figure 5 , the main effect remained in studies of lung cancer (positive/high nestin vs. negative/ low nestin: OR = 2.00, 95% CI = 1.16-3.44, P = 0.01).
More importantly, regarding to focus at the association of nestin with lung cancer staging, as shown in Figure 6 , we have done some analysis on the relationship between nestin and T staging or N staging. In the analysis stratified by T staging (T 3-4 vs. T 1-2 ) in lung cancer, the main effect remained (positive/high nestin vs. negative/ low nestin: OR = 3.73, 95% CI = 1.42-9.74, P = 0.007). Meanwhile, in the analysis stratified by N staging (N 1-2 vs. N 0 ) in lung cancer, the main effect remained (positive/ high nestin vs. negative/low nestin: OR = 2.73, 95% CI = 1.39-5.37, P = 0.004).
Tests of heterogeneity
Tests of heterogeneity between trials using the Q statistic showed no significant heterogeneity in the following analyses: nestin expression with cancer staging (positive/high nestin vs. negative/low nestin, P = 0.76, www.impactjournals.com/oncotarget I 2 = 0%), nestin expression with lymph node positivity (positive/high nestin vs. negative/low nestin (P = 0.67, I 2 = 0%), and nestin expression with lung cancer stage, positive/high nestin vs. negative/low nestin (P = 0.98, I 2 = 0%). Accordingly, data were analyzed using a fixed-effects model.]
Publication bias
Funnel plots were performed to assess publication bias. As show in Figure 3 
DISCUSSION
TNM stage is determined according to the outcomes of physical examination, biopsy, and imaging tests; in clinical application, a pathological report is the basis of TNM staging. [27] In addition to anatomic tumor categories, most sites and tumor types are N 1-2 vs. N 0 ) . The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
classified according to TNM stage,with the anatomic extent of the tumor determining the cancer stage. [1, 2] Clearly distinguishing between stages and reliably estimating survival probability require that each stage be homogeneous. Stages I to III correspond to progressively advanced localized and regional cancer, whereas stage IV corresponds to systemic metastases. An accurate staging system is important for guiding physicians in treatment options and determining patients' prognosis. [28] Nestin was initially discovered based on its expression in neural progenitor cells, where it was considered a marker for distinguishing precursor cells from differentiated cells. [29, 30] N 1-2 vs. N 0 ) . The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
reported, only one clinical study by Karsten et al. demonstrated a significant relationship between high nestin levels and cancer stage. [24] Our aim here was to clarify the relationship between nestin and cancer stage by performing a meta-analysis of the literature in the field. This analysis provided evidence of an association between positive/high nestin and median/advanced cancer stage in different cancers, demonstrating a significant main effect of positive/high nestin versus negative/low nestin. Analyses of nestin association stratified according to lymph node involvement (N 1-2 vs. N 0 ) and cancer category were also statistically significant.
The relationships established here suggest that positive/high nestin can be used as an added factor in determining TNM stage and judging cancer malignancy, especially for lung cancer. Regarding to focus at the association of nestin with lung cancer staging, we have done some analysis on the relationship between nestin and T staging or N staging. Analyses of nestin association stratified according to T staging (T 3-4 vs. T 1-2 ) or N staging (N 1-2 vs. N 0 ) and lung cancer category were also statistically significant. This analysis provided evidence of an association between positive/high nestin and median/ advanced cancer stage in lung cancer, demonstrating a significant main effect of positive/high nestin versus negative/low nestin. Further investigations of nestin and lung cancer stage on a larger scale are needed to verify this result and firmly establish nestin as a cancer malignancy biomarker.
Some limitations of this meta-analysis should be noted. Firstly, this meta-analysis was based on pooled positive or high nestin data; thus, we were only able to address the relationship between positive/high nestin and cancer stage, and not individual positive or high-nestin values. Secondly, a small-study effect, in which results reported in smaller studies have a disproportionate effect on the final analysis, could not be avoided because of the relatively small size of some of the studies. Ultimately, additional large scale-studies with more detailed individual data are warranted to further validate the relationship of nestin with cancer stage.
CONCLUSIONS
In summary, our meta-analysis provides evidence of an association between positive/high nestin and cancer stage, suggesting that knowledge of nestin expression status could facilitate cancer staging, especially in lung cancer.
MATERIALS AND METHODS
Publication search
Relevant articles published as of June 2014 were retrieved from multiple databases, including PubMed, ISI Web of Knowledge, Embase, and the Chinese National Knowledge Infrastructure (CNKI) using the keywords nestin, malignancy, neoplasm, cancer staging and TNM staging. Articles with case-control or cohort studies related to the association of positive/high nestin and cancer staging were collected.
Inclusion criteria
The following criteria were used to select publications for further meta-analysis: (1) published in English or Chinese, regardless of publication date; (2) evaluated associations between positive/high nestin and cancer stage; (3) confirmed cancer patients pathologically; (4) included detailed cancer/TNM staging data; and (5) contained at least two comparison groups (positive-nestin group vs. negative-nestin group, or high-nestin group vs. low-nestin group).
Data collection
Publication details such as the first author's name, publication year, patients' country of origin and ethnicity, total number of patients, cancer type, median/mean age of the study population, and disease stage were collected for each eligible publication. Positive or high nestin and cancer/TNM stage were end points of interest.
Statistical analysis
Patients were divided into positive/high nestin and negative/low nestin groups, and the associations between positive/high nestin and cancer stage were measured by determining odds ratios (ORs) with 95% confidence intervals (CIs). The significance of pooled ORs was determined by the Z test. Statistical heterogeneity among studies was assessed using Q and I 2 statistics, where variation due to heterogeneity or random error identified with Q tests were further defined according to I 2 values, as follows: I 2 = 0-25%, no heterogeneity; I 2 = 25-50%, moderate heterogeneity; I 2 = 50-75%: large heterogeneity; and I 2 = 75-100%, extreme heterogeneity. [26] A fixedeffects model was applied in the initial analysis, and if significant heterogeneity existed, a confirmed randomeffects model was used. Publication bias was evaluated using funnel plots. All statistical analyses were carried out with Review Manager version 5.0 (Revman; The Cochrane Collaboration, Oxford, UK). All P-values in the meta-analysis were two-sided, and a P-value < 0.05 was considered significant.
